timothy sykes logo
DataMeds AI Stock Surges As Revenue And Oncology Bets Ignite Thumbnail
G Google News

DataMeds AI Stock Surges As Revenue And Oncology Bets Ignite

JACK KELLOGG•UPDATED OCT. 12, 2026, 7:48 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

DataMeds AI Inc. stocks have been trading up by 11.82 percent after unveiling a breakthrough healthcare diagnostics AI platform.

Key Takeaways

  • Corexa Pharmacy topped $1M in preliminary September revenue, more than 66% above July, signaling rapid scaling of the MEDS pharmacy engine.
  • Completion of the $1.5M Helomics acquisition gives MEDS an AI‑driven cancer diagnostics lab plus $1.5M in cash, without taking on legacy third‑party debt.
  • Litigation tied to the 2023 Wellgistics deal was settled, wiping out about $19M in liabilities and retiring 364,099 shares for a $450,000 cash payment.
  • Launch of the “Health Lives Here” GLP‑1 telehealth app with Tollo Health sent MEDS shares up more than 20% on strong trading volume.
  • MEDS stock spiked roughly 300% after closing the Helomics deal, underscoring intense momentum and elevated volatility for active traders.

Candlestick Chart

Live Update At 07:48:00 EDT: On Monday, October 12, 2026 DataMeds AI Inc. stock [NASDAQ: MEDS] is trending up by 11.82%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MEDS has turned into a classic high‑volatility story name, but there is real revenue behind the hype. DataMeds AI reported that its Corexa Pharmacy unit generated more than $1M in preliminary, unaudited revenue in 2026/09, over 66% higher than July. For a micro‑cap like MEDS, that kind of month‑to‑month acceleration matters. It tells traders the pharmacy engine is not just a slide‑deck idea.

The flip side is the financial quality. Recent filings show MEDS with about $23.3M in annual revenue but brutal margins. Profitability ratios are deep in the red, with profit margin above negative 1,000% and EBIT margin worse than negative 1,000%. Cash flow from operations is negative, free cash flow runs around negative $3.1M, and the current ratio near 0.1 highlights tight liquidity.

More Breaking News

On the chart, MEDS has been a rollercoaster. After a huge mid‑September spike, daily candles between 2026/09/17 and 2026/10/09 show the stock fading from above $6 back into the $2–$4 range. Intraday five‑minute data reveals wide swings of more than $1 in minutes, ideal for nimble day traders who respect risk and cut losses quickly.

Why Traders Are Watching MEDS Right Now

DataMeds AI is suddenly on a lot of watchlists because the story flipped from quiet micro‑cap to multi‑catalyst momentum play. The Helomics deal is the centerpiece. MEDS paid $1.5M in stock and notes to Axe Compute, but in return it received an AI‑driven, CLIA/CAP‑certified cancer diagnostics lab, a central lab CRO business, and $1.5M in cash. No third‑party debt, no ugly legacy payables beyond normal expenses. That structure explains why traders treated Helomics like a game‑changer.

When MEDS announced completion of the Helomics acquisition in mid‑September, shares exploded more than 300% on extraordinary trading volume. At one point, premarket moves around the news showed MEDS up more than 300%, turning it into a momentum magnet. Those kinds of spikes rarely come from headlines alone; they come when shorts scramble and day traders pile in.

At the same time, MEDS is cleaning up its past. The Wellgistics litigation settlement erased roughly $19M in liabilities and retired 364,099 shares for just $450,000 in cash. Traders love when a small cap removes a big legal overhang and tightens the float.

On the growth side, the Corexa Pharmacy update showed more than $1M in September revenue, up over 66% versus July, which pushed MEDS about 35% higher premarket after the report. Add in the “Health Lives Here” app with Tollo Health — targeting GLP‑1 users and later Long COVID and cancer — and you get a vision of an AI‑powered telehealth, pharmacy, and oncology ecosystem. For momentum traders, that combination of narrative, revenue acceleration, and cleaned‑up balance sheet is exactly what fuels big swings.

Conclusion

Right now MEDS sits at the crossroads of aggressive growth plans and harsh financial reality. DataMeds AI has stitched together Corexa Pharmacy, the Helomics oncology lab, and the “Health Lives Here” telehealth app into a single story: AI‑driven, end‑to‑end care from GLP‑1 scripts to cancer diagnostics. The company has also settled the Wellgistics dispute, removing roughly $19M of liabilities and trimming share count, while launching a new AI‑focused website and planning a high‑profile telehealth summit appearance.

At the same time, MEDS still runs with negative margins, heavy losses, and a tight liquidity profile. That tension is exactly why the stock can jump 300% on one catalyst and then give back a big chunk as traders lock in profits. The recent meme‑style Dream Bowl Meme Coin I token distribution highlights that DataMeds AI is not afraid to lean into speculative themes, which some traders love and others avoid.

For active traders studying MEDS, the key is preparation. Map levels, study how the stock reacted to the Helomics news, the Corexa revenue update, and the GLP‑1 app launch, and assume volatility remains elevated. As Tim Sykes likes to remind his community, “The market rewards those who are prepared, not those who show up hoping for luck.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. Use the MEDS story as a live case study in how catalysts, charts, and risk management all intersect — strictly for educational and research purposes, not as trading advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”